Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.69 |
| ▸ | PGR | P06401 | 6/20 | 0.69 |
| ▸ | USP2 | O75604 | 5/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobetasone Butyrate SCHEMBL11750078 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL36599 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL29572705 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL11124627 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL448850 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL14339619 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL732359 | 0.96 | LMNA (0.92) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL568167 | 0.94 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL28099304 | 0.94 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL11748908 | 0.93 | LMNA (0.87) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-3943073-B1 | BIODEGRADABLE POLYMER MICROPARTICLE CONTAINING STEROID-BASED DRUG AND PREPARATION METHOD THEREFOR | REGENBIOTECH INC (KR) | 2025-03-26 | — | — | EP | claimed |
| EP-4178579-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4013420-B1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | claimed |
| EP-3407890-B1 | PHARMACEUTICAL PREPARATION AND THE USE THEREOF FOR TREATING VIRAL LARYNGITIS | SOMMER PETER (DE) | 2023-07-19 | — | — | EP | claimed |
| EP-3068437-B2 | SPRAYABLE TOPICAL CARRIER AND COMPOSITION COMPRISING PHOSPHATIDYLCHOLINE | LIPIDOR AB (SE) | 2022-07-06 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-12533372-B2 | Biological polysaccharide for preventing and treating acne and steroid- dependent dermatitis and use thereof | Boman (Zhejiang) Biotechnology Co., Ltd. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK SLAVE PTY LTD (AU) | 2025-12-18 | — | — | US | disclosed |
| US-12364696-B2 | Treatment of autoimmune disease | JAK SLAVE PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-20250213572-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025088039-A1 | HIGHLY CONCENTRATED DERMALLY APPLICABLE PERMETHRIN PREPARATION WITH AN INCREASED DRUG LOAD IN THE TARGET COMPARTMENT FOR IMPROVED TREATMENT OF ECTOPARASITE INFESTATION | INFECTOPHARM ARZNEIMITTEL UND CONSILIUM GMBH (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-3407890-B1 | PHARMACEUTICAL PREPARATION AND THE USE THEREOF FOR TREATING VIRAL LARYNGITIS | SOMMER PETER (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4034086-A1 | FORMULATION | HEWLETT HEALTHCARE LIMITED (GB) | 2022-08-03 | — | — | EP | disclosed |
| CN-108341739-B | Preparation method of alpha-aryl, heteroaryl or alkenyl-alpha, alpha-difluoromethyl compound | 中国科学院上海有机化学研究所 | 2022-07-19 | — | — | CN | disclosed |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK SLAVE PTY LTD (AU) | 2022-05-12 | — | — | US | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
| WO-2022059618-A1 | COAT-FORMING AEROSOL COMPOSITION AND AEROSOL TYPE COAT-FORMING TOPICAL FORMULATION | 久光製薬株式会社 | 2022-03-24 | — | — | WO | disclosed |
| WO-2022050376-A1 | DRUG DELIVERY METHOD USING LIGHT, AND TARGET ACCUMULATION TYPE COMPLEX | 国立大学法人東海国立大学機構 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364696-B2 | Treatment of autoimmune disease | JAK1, JAK3, JAK2 | LMNA 4676/4885MAPT 2566/4885SMN1; SMN2 4724/4885 |
| US-20250381192-A1 | Treatment of Autoimmune Disease | JAK1, JAK3, JAK2 | LMNA 4676/4885MAPT 2566/4885SMN1; SMN2 4724/4885 |
| US-20250213572-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | LMNA 1873/4885MAPT 589/4885SMN1; SMN2 3626/4885 |
| US-12533372-B2 | Biological polysaccharide for preventing and treating acne and steroid- dependent dermatitis and use thereof | CYP17A1, SHBG, CUTA | LMNA 3215/4885MAPT 3973/4885SMN1; SMN2 4879/4885 |
| US-20220143025-A1 | TREATMENT OF AUTOIMMUNE DISEASE | JAK1, JAK3, JAK2 | LMNA 4676/4885MAPT 2566/4885SMN1; SMN2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.